ICH Q12 Lifecycle Management for EAEU Pharma — Established Conditions, PACMP and What to Do Now
Imagine this: a manufacturer wants to change the supplier of an excipient. They are not changing the drug itself, not touching the dosage, not moving to a different site. Simply a different supplier of lactose. In most regulatory systems, this will trigger a variation application, a regulatory review, and months of waiting. Multiply that by dozens of drugs in a portfolio — and you get an idea of how much administrative resource is spent on changes that have no effect on quality or safety whatsoever.
ICH Q12 emerged precisely as an answer to this problem. The guidance «Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management» was adopted at Step 5 in November 2019. Its core idea is simple: the depth of regulatory oversight of changes should correspond to the actual risk to product quality, rather than being built on the principle that «any change requires approval.»
For manufacturers operating in the EAEU market, this guidance is now doubly relevant — the Union is moving towards its implementation, and understanding the logic of the new approach in advance is worth the effort.
How change management works today
The traditional model is based on a detailed description of the manufacturing process in the registration dossier. In practice, the dossier becomes a «photograph» of production at the time of registration: specific substance suppliers, specific equipment, specific parameters. Any deviation from this «photograph» requires interaction with the regulator.
In practice, this creates several well-known problems.
First, any process improvement becomes an administrative event. A manufacturer introduces a more modern analytical control method — a variation must be filed. They switch to equipment of the same category but from a different manufacturer — another variation. The logic is understandable from an oversight perspective, but in practice it slows down exactly those changes aimed at improving quality.
Second, companies with a global presence see their regulatory dossiers multiply for different markets. FDA, EMA, EAEU, China — every regulator has its own classification of changes, its own timelines, its own documentation requirements. A single change in the manufacturing process may require from two to six parallel applications to different authorities. Synchronizing them is practically impossible.
Third, predictability suffers. A manufacturer does not know in advance how long the review of a variation will take, what questions the expert will raise, or how many times the documentation will need to be revised. Planning manufacturing upgrades under these conditions is genuinely difficult.
What ICH Q12 proposes
The guidance introduces three interconnected tools. Each can be used independently, but together they create a fundamentally different system of change management.
Established Conditions (ECs)
The first tool establishes a clear demarcation of information within the dossier. Established Conditions (hereinafter — ECs) are those elements of the manufacturing process description that genuinely affect the quality, safety, and efficacy of the drug. Only a change to the ECs requires regulatory notification. Everything else — supporting information — the manufacturer is entitled to change within their own quality system, without any interaction with the regulator.
It sounds simple, but defining what goes into the ECs — and what does not — is where most of the practical work lies. ICH Q12 describes two approaches.
The Basic Approach assumes a broader list of ECs. The manufacturer defines them conservatively: significant process parameters, essential raw material characteristics, main analytical methods. This approach will generate more variation applications, but is easier to argue before the regulator.
The Enhanced Approach is built on deep process understanding — the kind accumulated through work under ICH Q8 (pharmaceutical development) and Q10 (pharmaceutical quality system). If a manufacturer can demonstrate with documented justification that a specific parameter does not affect product quality across a wide range of values, it does not need to be included in the ECs. The result is significantly fewer regulatory interactions when changes arise.
The difference between the two approaches is clearly visible in this example:
| Situation | Basic Approach | Enhanced Approach |
|---|---|---|
| Change of excipient supplier (not included in ECs) | Variation application | Internal quality system procedure |
| Change of mixing time (range in ECs set broadly) | Variation application | Internal procedure |
| Change of batch size (outside EC range) | Variation application | Variation application |
| Change of manufacturing site | Variation application | Variation application |
Post-Approval Change Management Protocol (PACMP)
The second tool — PACMP — allows the strategy for future changes to be agreed upon as early as the registration stage or immediately after it. The manufacturer describes: what they plan to change, how they will assess the acceptability of the change, and what data they will submit to the regulator. The regulator evaluates and approves this plan.
When the change actually occurs, the manufacturer implements it according to the pre-agreed algorithm. The volume of regulatory interaction drops to a minimum: instead of a full regulatory review, a notification is sufficient.
For biological drugs, this is particularly valuable. A change of cell bank supplier or a modification of fermentation parameters traditionally triggers lengthy comparability studies and a prolonged review. PACMP allows the criteria for such studies to be agreed upon in advance, so that the comparability data themselves simply confirm an already-approved plan.
Pharmaceutical Lifecycle Management Document (PLM Document)
The third tool — the PLM document — is a structured registry of all ECs, the manufacturer’s commitments, and the history of dossier changes. It ensures continuity: when, ten years after registration, it becomes necessary to understand why conditions were fixed a certain way and what has changed since, the PLM document provides the answer.
In the longer term, the PLM document is intended to integrate into the eCTD structure — the electronic format of the technical dossier. This turns it from an archival file into a living part of the registration package.
How this looks globally — and where the EAEU stands now
FDA released its final guidance on ICH Q12 in May 2021. Use of the tools is voluntary, but the agency actively encourages PACMP for technological changes in biological drug manufacturing and the gradual introduction of Process Analytical Technology (PAT).
EMA integrated Q12 with the existing EU Variations Regulation. The main challenge was aligning the EC concept with the already established variation classification (Type IA, IB, II). Manufacturers in the EU now actively apply PACMP for dossiers registered under the centralized procedure.
Health Canada chose a phased path: first PACMP for biological and radiopharmaceutical drugs (2024–2025), then expansion to all other categories.
The overall picture looks like this:
| Region | Q12 Implementation Status | Priority Area |
|---|---|---|
| USA (FDA) | Adopted, voluntary use since 2021 | Biological drugs, PAT |
| EU (EMA) | Adopted, integrated with EU Variations Regulation | Centralized procedures |
| Canada | Phased implementation, 2024+ | Biological and radiopharmaceutical drugs |
| EAEU | Under methodological development | Active discussion in the expert community |
In the EAEU, the situation is more complex. The legal foundation — Council Decision of the Eurasian Economic Commission No. 78 dated 03.11.2016 «On the Rules for the Registration and Expert Evaluation of Medicines for Medical Use» — establishes a rigid classification of dossier changes. Council Decision No. 34 dated 22.05.2025 (entered into force on June 21, 2025) took a step toward flexibility: manufacturers can now initiate changes to the registration dossier before the recognition procedure in other Member States is completed, without waiting for its conclusion. Council Decision No. 93 dated 26.11.2025 introduced further amendments to the same Rules. This represents movement toward a more manageable lifecycle approach, but full implementation of the EC and PACMP concepts in EAEU law has not yet occurred.
At RegLek conferences between 2021 and 2025, experts from the NCEMP (National Centre for Expert Evaluation of Medicinal Products) of the Russian Ministry of Health regularly discuss Q12 methodology — how to identify ECs in Eurasian dossiers, how to assess the maturity of a manufacturer’s quality system. This is a signal: the topic is not theoretical, work is in progress.
The transition to eCTD 4.0 in the EAEU is building the technical infrastructure for the PLM document. Once the legal framework is in place, deploying the new tool will be straightforward.
What this changes for manufacturers — and what stays the same for now
Right now, ICH Q12 is not operational in its full scope in the EAEU. Manufacturers who have registered a drug under Decision No. 78 are required to comply with the current variation classification. Taking something outside the scope of regulatory oversight on the grounds that «it is not an EC» is not yet possible.
But preparing now — without waiting for the corresponding EEC document — makes good sense. The reasons are several.
A dossier structured with Q12 logic is better organized. It clearly shows which process parameters genuinely affect quality and which were documented out of excessive caution — and this facilitates interaction with reviewers even under current rules. Companies already registered with FDA or in the EU using PACMP or the EC concept will have a clear advantage when EAEU rules are adopted: the work of identifying ECs will already have been done.
And one more argument that is often overlooked. The logic of PACMP is essentially strategic change planning. Even without a formal protocol, a manufacturer can conduct such planning internally: identify in advance which changes are likely within the next three to five years, what data will be needed, and when accumulation of that data should begin.
What to do right now
1. Conduct an audit of your variation portfolio for the last three years. Calculate how many variation applications you submitted during that period and break them down by type: manufacturing process changes, supplier replacements, analytical method updates, storage condition adjustments. This will reveal where administrative burden is concentrated and how actively you are managing the lifecycle of your products.
2. Select two or three drugs as a pilot for EC analysis. Choose well-studied products — ideally those with accumulated stability and process data. Apply the ICH Q12 logic: which parameters in the dossier genuinely affect quality, and which are fixed «just in case»? This analysis carries no regulatory consequences now, but builds a methodological foundation.
3. Assess the maturity of your Pharmaceutical Quality System (PQS) against Q12 criteria. The Enhanced Approach to ECs is available only to manufacturers with a mature PQS capable of managing changes without regulatory oversight. Ask yourself: is there a formalized risk assessment procedure for CMC changes (Chemistry, Manufacturing and Controls)? Is accumulated process knowledge documented? Are periodic product quality reviews (APR / PQR — Annual Product Review / Product Quality Review) conducted?
4. Monitor EEC documents. Council Decision No. 34 dated 22.05.2025 has already moved change management toward greater flexibility. Expect methodological recommendations on Q12 to emerge — either as an EEC decision or a Board recommendation. Subscribe to updates at eec.eaeunion.org in the section on regulatory documents for medicines circulation.
5. Put the topic on the agenda of your internal regulatory strategy meetings. Q12 changes not only procedures, but how a company thinks about its products. Moving from the logic of «registered and forgotten» to «actively managing the lifecycle» requires a shift in culture within regulatory departments. That conversation is better started before the official rules arrive.
The lifecycle of a medicinal product does not end on the day the registration certificate is issued. ICH Q12 offers tools that bring regulatory rules into alignment with how modern pharmaceutical manufacturing actually works. For companies ready to invest in understanding this approach now, the moment EAEU rules are adopted will be an anticipated milestone, not an unexpected challenge.
Normative base:
1. ICH Q12 «Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management,» Step 5, November 2019 (ich.org)
2. Decision of the Council of the Eurasian Economic Commission No. 78 dated 03.11.2016 «On the Rules for the Registration and Expert Evaluation of Medicines for Medical Use» (as amended on 26.11.2025)
3. Decision of the Council of the Eurasian Economic Commission No. 34 dated 22.05.2025 «On Amending Decision of the Council of the Eurasian Economic Commission No. 78 dated November 3, 2016» (entered into force on 21.06.2025)
4. Decision of the Council of the Eurasian Economic Commission No. 93 dated 26.11.2025 «On Amending the Rules for the Registration and Expert Evaluation of Medicines for Medical Use»
5. ICH Q8(R2) «Pharmaceutical Development,» ICH Q9 «Quality Risk Management,» ICH Q10 «Pharmaceutical Quality System» (ich.org)